Health Care [ 3/12 ] | Health Care Equipment & Supplies [ 22/74 ]
NASDAQ | Common Stock
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally.
Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols.
It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing.
MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 7, 24 | -0.11 Increased by 0.00% | -0.12 Increased by +11.29% |
| Aug 6, 24 | -0.09 Increased by +10.00% | -0.13 Increased by +30.77% |
| May 7, 24 | -0.09 Increased by +18.18% | -0.13 Increased by +30.77% |
| Mar 12, 24 | -0.05 Increased by 0.00% | -0.07 Increased by +28.57% |
| Nov 8, 23 | -0.11 Decreased by -83.33% | -0.10 Decreased by -10.00% |
| Aug 9, 23 | -0.10 Decreased by -25.00% | -0.10 |
| May 10, 23 | -0.11 Decreased by -175.00% | -0.11 |
| Mar 15, 23 | -0.05 Increased by 0.00% | -0.07 Increased by +28.57% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 8.16 M Increased by +1.99% | -11.56 M Decreased by -2.71% | Decreased by -141.56% Decreased by -0.71% |
| Jun 30, 24 | 10.43 M Increased by +15.33% | -9.38 M Increased by +10.81% | Decreased by -89.89% Increased by +22.67% |
| Mar 31, 24 | 11.34 M Increased by +32.25% | -9.53 M Decreased by -10.95% | Decreased by -83.99% Increased by +16.11% |
| Dec 31, 23 | 15.67 M Increased by +26.10% | -5.28 M Decreased by -83.96% | Decreased by -33.68% Decreased by -45.88% |
| Sep 30, 23 | 8.00 M Decreased by -24.79% | -11.25 M Decreased by -118.26% | Decreased by -140.57% Decreased by -190.19% |
| Jun 30, 23 | 9.04 M Decreased by -5.88% | -10.51 M Decreased by -35.09% | Decreased by -116.25% Decreased by -43.53% |
| Mar 31, 23 | 8.58 M Decreased by -25.99% | -8.59 M Decreased by -115.97% | Decreased by -100.11% Decreased by -191.80% |
| Dec 31, 22 | 12.42 M Increased by +22.38% | -2.87 M Increased by +41.15% | Decreased by -23.09% Increased by +51.91% |